Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

Abstract: Systems, methods, and devices include a reconfigurable multi-purpose surgical tool with a housing having a plurality of portions for a plurality of surgical tools, such as a cautery tool, a scalpel tool, and/or a forceps tool. A first portion of the housing can house a first surgical tool. The first surgical tool is converted between an in-use configuration and a stored configuration. The stored configuration includes a first surgical tool portion of the first surgical tool being at least partially contained by the housing. The in-use configuration being when the first surgical tool portion is at least partially exposed from the housing. A second portion of the housing partially houses a second surgical tool. The second surgical tool includes another in-use configuration with the second surgical tool at least partially exposed from the housing. A third portion of the housing at least partially houses a third surgical tool.

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”) —such as, e.g., a fully human-glycosylated (HuGly) anti-h VEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Various embodiments relate to a device for simultaneous consumption of a fluid and a frozen substance. in some embodiments, the device can include a handle assembly and a variable-volume chamber configured to store at least a portion of the fluid substance, the variable-volume chamber removably connected to the handle assembly. A cover can be removably coupled with the handle assembly. The cover can have an open end and a closed end and can at least partially define a mold cavity for molding the freezable substance.

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (ID-UA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: A system, methods, and techniques are provided for performing automated operations to track one or more physiological indicators of a user via hardware capabilities of a computing device associated with the user, and/or of external monitoring devices communicatively coupled to such a user computing device. Feedback regarding such tracked activities may be provided to the user via one or more guided physiological and/or exercises. The system may enable the user to interactively create and/or experience audiovisual artworks that may include still images, music, dynamic sound effects, and animations, such as animations depicting the creation of one or more related artworks.

Abstract: Various embodiments relate to a device for simultaneous consumption of a fluid and a frozen substance. In some embodiments, the device can include a squeezable chamber configured to store at least a portion of the fluid substance. A flange can be connected at a first end to the squeezable chamber. The flange can define a cavity in fluid communication with an interior of the squeezable chamber such that, when the squeezable chamber is squeezed by a user, the fluid substance is driven from the squeezable chamber and through at least a portion of the cavity defined by the flange. In some embodiments, one or more optical emitters can be coupled with the device.

Abstract: An apparatus for consuming a freezable substance is disclosed. The apparatus can comprise a squeezable chamber configured to store a liquid. The apparatus can comprise a flange coupled to or formed with the squeezable chamber, the flange sized and shaped to support the freezable substance. The apparatus can comprise a liquid pathway from the squeezable chamber through the flange to deliver the liquid to the freezable substance.

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothclial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment-to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.